Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer

NCT ID: NCT00777101

Last Updated: 2018-08-09

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

233 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-02-04

Study Completion Date

2018-06-03

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a study of an experimental drug (neratinib) versus a combination of drugs (lapatinib and capecitabine) in women who have erbB-2 (HER-2) positive metastatic or locally advanced breast cancer. The goal of this study is to compare the two regimens in shrinking tumors and extending the lives of women with erbB2 (HER2) positive breast cancer. The study will also compare the safety of the two regimens and to compare quality of life of patients taking the two regimens.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Advanced Breast Cancer Breast Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Neratinib

Group Type EXPERIMENTAL

Neratinib

Intervention Type DRUG

Tablets 240 mg orally once per day until disease progression or unacceptable toxicity

Lapatinib plus Capecitabine

Group Type ACTIVE_COMPARATOR

Lapatinib

Intervention Type DRUG

Tablets 1250 mg orally once per day until disease progression or unacceptable toxicity.

Capecitabine

Intervention Type DRUG

Tablets 2000 mg/m² given orally in two evenly divided daily doses for first 14 days of each 21 day cycle. Given until disease progression or unacceptable toxicity.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Neratinib

Tablets 240 mg orally once per day until disease progression or unacceptable toxicity

Intervention Type DRUG

Lapatinib

Tablets 1250 mg orally once per day until disease progression or unacceptable toxicity.

Intervention Type DRUG

Capecitabine

Tablets 2000 mg/m² given orally in two evenly divided daily doses for first 14 days of each 21 day cycle. Given until disease progression or unacceptable toxicity.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

HKI-272 Tykerb, Tyverb Xeloda

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Stage IIIB, IIIC, or IV erbB2 (HER2) positive breast cancer
* Prior use of Herceptin (trastuzumab), and a taxane
* Adequate cardiac and renal function

Exclusion Criteria

* More than 2 prior Herceptin (trastuzumab) regimens or prior use of Xeloda (capecitabine) and / or Tykerb (lapatinib) \[Tyverb\]
* Bone as the only site of disease
* Active central nervous system metastases (subjects should be stable and off anticonvulsants and steroids)
* Significant gastrointestinal disorder with diarrhea as major symptom
Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Puma Biotechnology, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Puma

Role: STUDY_DIRECTOR

Biotechnology

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Arizona Oncology Associates HOPE

Tucson, Arizona, United States

Site Status

Southwest Cancer Care

Murrieta, California, United States

Site Status

UC Irvine Medical Center

Orange, California, United States

Site Status

Aptium Oncology/Comprehensive Cancer Center at Desert Regional Medical Center

Palm Springs, California, United States

Site Status

Redwood Regional Medical Group, Inc.

Santa Rosa, California, United States

Site Status

Rocky Mountain Cancer Center

Denver, Colorado, United States

Site Status

Hematology Oncology Associates, P.C.

Stamford, Connecticut, United States

Site Status

Palm Beach Institute of Hematology & Oncology

Boynton Beach, Florida, United States

Site Status

Robert R. Carroll, MD, PA

Gainesville, Florida, United States

Site Status

University of Florida

Jacksonville, Florida, United States

Site Status

Hematology Oncology Associates

Loxahatchee Groves, Florida, United States

Site Status

Mercy Research Institute

Miami, Florida, United States

Site Status

Cancer Centers of Florida

Orlando, Florida, United States

Site Status

Hematology Oncology Associates of the Treasure Coast

Port Saint Lucie, Florida, United States

Site Status

Cancer Care Specialists Of Central Illinois

Decatur, Illinois, United States

Site Status

Oncology Specialists, SC

Park Ridge, Illinois, United States

Site Status

Midwestern Regional Medical Center

Zion, Illinois, United States

Site Status

Central Indiana Cancer Centers

Fishers, Indiana, United States

Site Status

Hematology Oncology of Indiana

Indianapolis, Indiana, United States

Site Status

Floyd Memorial Cancer Center of Indiana

New Albany, Indiana, United States

Site Status

Ashland-Bellefonte Cancer Center

Ashland, Kentucky, United States

Site Status

Owsley Brown Frazier Cancer Center (OBFCC)

Louisville, Kentucky, United States

Site Status

Purchase Cancer Group

Paducah, Kentucky, United States

Site Status

Missouri Cancer Associates

Columbia, Missouri, United States

Site Status

Capitol Comprehensive Cancer Care Clinic

Jefferson City, Missouri, United States

Site Status

Arena Oncology Associates, PC

Lake Success, New York, United States

Site Status

Weill Cornell Medical College New York-Presbyterian Hospital Weill, Cornell Breast Center

New York, New York, United States

Site Status

New York Oncology Hematolgy, PC

Troy, New York, United States

Site Status

Oncology Partners Network

Cincinnati, Ohio, United States

Site Status

MetroHealth Medical Center, Cancer Care Center

Cleveland, Ohio, United States

Site Status

University of Oklahoma Health Sciences Center Dept. of Hematology Oncology

Oklahoma City, Oklahoma, United States

Site Status

Northwest Cancer Specialists, PC

Portland, Oregon, United States

Site Status

Lancaster Cancer Center

Lancaster, Pennsylvania, United States

Site Status

Allegheny General Hospital Allegheny Cancer Center

Pittsburgh, Pennsylvania, United States

Site Status

Cookeville Regional Medical Center

Cookeville, Tennessee, United States

Site Status

Center for Biomedical Research

Knoxville, Tennessee, United States

Site Status

Thompson Cancer Survival Center Thompson Oncology Group

Knoxville, Tennessee, United States

Site Status

University of Tennessee Cancer Institute

Memphis, Tennessee, United States

Site Status

Texas Oncology, P.A.

Austin, Texas, United States

Site Status

El Paso Cancer Treatment Center - West

El Paso, Texas, United States

Site Status

The Center for Cancer and Blood Disorders

Fort Worth, Texas, United States

Site Status

HOPE Oncology

Richardson, Texas, United States

Site Status

Cancer Care Network of South Texas-HOAST

San Antonio, Texas, United States

Site Status

East Texas Medical Center Cancer Institute, Tyler Hematology Oncology

Tyler, Texas, United States

Site Status

Mater Private Centre for HOCA

South Brisbane, Queensland, Australia

Site Status

Medical Oncology Royal Adelaide Hospital

Adelaide, South Australia, Australia

Site Status

Western Hospital

Footscray, Victoria, Australia

Site Status

Mount Hospital

West Perth, , Australia

Site Status

AKH Wien Universitaetsklinik fuer Innere Medizin I Klinische Abteilung für Onkologie

Vienna, , Austria

Site Status

Institut Jules Bordet Unite du Chimiotherapie

Brussels, , Belgium

Site Status

District Dispensary for Oncology Diseases Internal Unit- Sofia EOOD, Dept. of Chemotherapy

Sofia, , Bulgaria

Site Status

UMHAT Tzaritza Yoanna

Sofia, , Bulgaria

Site Status

Interdistrict Dispensary for Oncology Diseases -Internal Unit- Department Oncotherapy and Palliative Care

Varna, , Bulgaria

Site Status

BC Cancer Agency - Vancouver Centre

Vancouver, British Columbia, Canada

Site Status

Centre Hospitalier Affilie Universitaire de Quebec Hopital du St-Sacrement

Québec, Quebec, Canada

Site Status

General Hospital Varazdin

Varaždin, , Croatia

Site Status

University Hospital Center Zagreb

Zagreb, , Croatia

Site Status

University Hospital Sestre Milosrdnice

Zagreb, , Croatia

Site Status

Fakultni nemocnice Olomouc Klinika onkologie

Olomouc, , Czechia

Site Status

Centre Oscar Lambret Departement de senologie

Lille, , France

Site Status

Centre Hospitalier Lyon Sud

Pierre-Bénite, , France

Site Status

CHU de Poitiers Service d'oncologie medicale

Poitiers, , France

Site Status

Institut Gustave ROUSSY Service de Pathologie mammaire

Villejuif, , France

Site Status

Universitaetsklinikum Hamburg-Eppendorf Klinik und Poliklinik fuer Gynaekologie

Hamburg, , Germany

Site Status

Nationales Centrum fuer Tumorerkrankungen Sektion Gynaekologische Onkologie

Heidelberg, , Germany

Site Status

Theagenio Anticancer Hospital of Thessaloniki

Thessaloniki, , Greece

Site Status

Department of Clinical Oncology, Tuen Mun Hospital

Hong Kong, , Hong Kong

Site Status

Queen Mary Hospital

Hong Kong, , Hong Kong

Site Status

UNIMED Medical Institute, Comprehensive Centre for Breast Diseases

Hong Kong, , Hong Kong

Site Status

Fovarosi Onkormanyzat Szent Janos Korhaza es Eszak-budai Egyesitett Korhazai, Onkologia

Budapest, , Hungary

Site Status

Orszagos Onkologiai Intezet "B" Belgyogyaszati osztaly

Budapest, , Hungary

Site Status

Bacs-Kiskun Megyei Korhaz Onkoradiologiai Kozpont

Kecskemét, , Hungary

Site Status

Josa Andras Oktatokorhaz / Onkoradiologiai Osztaly

Nyíregyháza, , Hungary

Site Status

Szegedi Tudomanyegyetem Onkoterapias Klinika

Szeged, , Hungary

Site Status

Hospital of County Veszprem

Veszprém, , Hungary

Site Status

Ospedale Misericordia e Dolce c/o UO Oncologia Medica

Prato, , Italy

Site Status

Istituto Regina Elena, Struttura Complessa Oncologia Medica A

Roma, , Italy

Site Status

National Hospital Organization Hokkaido Cancer Center

Sapporo, Hokkaido, Japan

Site Status

National Cancer Center Hospital

Tsukiji, Tokyo, Japan

Site Status

Aichi Cancer Center

Aichi, , Japan

Site Status

Chiba Cancer Center

Chiba, , Japan

Site Status

National Cancer Center Hospital East

Chiba, , Japan

Site Status

National Hospital Organization Kyushu Cancer Center

Fukuoka, , Japan

Site Status

Hiroshima City Hospital

Hiroshima, , Japan

Site Status

Hyogo Cancer Center

Hyōgo, , Japan

Site Status

Hakuaikai Medical Corporation Sagara Hospital

Kagoshima, , Japan

Site Status

Tokai University Hospital

Kanagawa, , Japan

Site Status

Kumamoto Municipal Hospital

Kumamoto, , Japan

Site Status

Kyoto University Hospital

Kyoto, , Japan

Site Status

Niigata Cancer Center Hospital

Niigata, , Japan

Site Status

National Hospital Organization Osaka National Hospital

Osaka, , Japan

Site Status

Saitama Cancer Center

Saitama, , Japan

Site Status

Shizuoka Cancer Center

Shizuoka, , Japan

Site Status

Jichi Medical University Hospital

Tochigi, , Japan

Site Status

St. Luke's International Hospital

Tokyo, , Japan

Site Status

The Cancer Institute Hospital of Japanese Foundation for Cancer Research Department of Medical Oncology

Tokyo, , Japan

Site Status

Tokyo Metropolitan Cancer&Infectious disease Ctr Komagome Hp

Tokyo, , Japan

Site Status

King Hussein Cancer Centre

Amman, , Jordan

Site Status

Oca Hospital / Monterrey International Research Center

Monterrey, Nuevo León, Mexico

Site Status

Bialostockie Centrum Onkologii im. M. Sklodowskiej-Curie w Bialymstoku Specjalistyczny Szpital Onkologiczn

Bialystok, , Poland

Site Status

Uniwersyteckie Centrum Kliniczne w Gdansku Klinika Onkologii i Radioterapii

Gdansk, , Poland

Site Status

Szpital Uniwersytecki w Krakowie Oddzial KIiniczny Kliniki Onkologii

Krakow, , Poland

Site Status

Centrum Onkologii Ziemi Lubelskiej im. SW. Jana z Dukli

Lublin, , Poland

Site Status

Metropolitan Oncology Center

San Juan, PR, Puerto Rico

Site Status

Institutul Oncologic "Prof. Dr. Alex. Trestioreanu"

Bucharest, , Romania

Site Status

Spitalul Universitar de Urgenta

Bucharest, , Romania

Site Status

Centrul de Oncologie Medicala

Iași, , Romania

Site Status

Spitalul Clinic Judetean

Sibiu, , Romania

Site Status

Scientific Research Institute of Oncology N.N. Petrov

Pesochny, Sankt-Peterburg, Russia

Site Status

Russian Oncology Research Centre of RAMS

Moscow, , Russia

Site Status

GUZ Perm Regional Oncology Dispensary

Perm, , Russia

Site Status

Ryazan State Medical University I.P.Pavlov of Federal Agency in Healthcare and Social Development

Ryazan, , Russia

Site Status

SIH Leningrad Regional Oncology Dispensary

Saint Petersburg, , Russia

Site Status

GUZ City Clinical Oncology Dispensary

Saint Petersburg, , Russia

Site Status

St. Petersburg State Medical University I.P.Pavlov of Roszdrav

Saint Petersburg, , Russia

Site Status

SIH Oncology Dispensary # 2 Of Department of Public Health

Sochi, , Russia

Site Status

Republican Clinical Oncology Dispensary of Ministry of Healthcare of Bashkortostan Republic

Ufa, , Russia

Site Status

Institute of Oncology and Radiology of Serbia

Belgrade, , Serbia

Site Status

Klinicko Bolnicki Centar (KBC) Bezanijska Kosa (Medical Centre ''Bezanijska Kosa'' (MCBK))

Belgrade, , Serbia

Site Status

Johns Hopkins Singapore International Medical Centre

Singapore, , Singapore

Site Status

Institute for Oncology Department for Medical Oncology

Ljubljana, , Slovenia

Site Status

The Medical Oncology Centre of Rosebank

Johannesburg, Gauteng, South Africa

Site Status

Eastleigh Breast Care Centre

Lynnwood, Gauteng, South Africa

Site Status

Hopelands Oncology Centre

Durban, KwaZulu-Natal, South Africa

Site Status

GVI Oncology Trial Unit Room 110 Panorama Medical Centre

Kraaifontein, Western Cape, South Africa

Site Status

National Cancer Center

Goyang-si, Gyeonggi-do, South Korea

Site Status

Samsung Medical Center

Seoul, Korea, South Korea

Site Status

Yonsei University Health System - Severance Hospital

Seoul, , South Korea

Site Status

Asan Medical Center

Seoul, , South Korea

Site Status

Hospital Germans Trias i Pujol Servicio de Oncologia

Badalona, Barcelona, Spain

Site Status

Corporacio Sanitaria Parc Tauli Servicio de Oncologia

Sabadell, Barcelona, Spain

Site Status

Hospital Mutua de Terrassa Servicio de Oncologia

Terrassa, Barcelona, Spain

Site Status

Hospital Central de Asturias Servicio de Oncologia, Planta Baja Oeste, Edificio Principal

Oviedo, Principality of Asturias, Spain

Site Status

Complejo Hospitalario U. de A Coruña Hospital Teresa Herrera Servicio de Oncologia

A Coruña, , Spain

Site Status

Hospital General Universitario de Alicante Servicio de Oncologia

Alicante, , Spain

Site Status

Hospital San Pedro de Alcantara Servicio de Oncologia

Cáceres, , Spain

Site Status

Hospital Provincial (Reina Sofia) Servicio de Oncologia

Córdoba, , Spain

Site Status

Hospital Universitario Dr. Josep Trueta Servicio de Oncologia

Girona, , Spain

Site Status

Centro Hospitalario de Jaen Servicio de Oncologia

Jaén, , Spain

Site Status

Hospital Gregorio Marañon Servicio de Oncologia

Madrid, , Spain

Site Status

Centro Oncologico M.D. Anderson Internacional

Madrid, , Spain

Site Status

Instituto Valenciano de Oncologia Servicio de Oncologia

Valencia, , Spain

Site Status

Hospital Clinico Universitario de Valencia Servicio de Hematologia y Oncologia

Valencia, , Spain

Site Status

Hospital Universitario Miguel Servet Servicio de Oncologia

Zaragoza, , Spain

Site Status

University of Lausanne Hospitals CHUV

Lausanne, , Switzerland

Site Status

Kantonsspital Winterthur Medizinische Onkologie

Winterthur, , Switzerland

Site Status

Abteilung fuer Onkologie Departement für Innere

Zurich, , Switzerland

Site Status

National Taiwan University Hospital

Taipei, , Taiwan

Site Status

Division of Medical Oncology, Department of Medicine

Bangkok Noi, Bangkok, Thailand

Site Status

Broomfield Hospital

Chelmsford, Essex, United Kingdom

Site Status

Royal Marsden NHS Foundation Trust & Institute of Cancer Research

London, , United Kingdom

Site Status

The Royal Marsden NHS Foundation Trust & Institute of Cancer Research

London, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Australia Austria Belgium Bulgaria Canada Croatia Czechia France Germany Greece Hong Kong Hungary Italy Japan Jordan Mexico Poland Puerto Rico Romania Russia Serbia Singapore Slovenia South Africa South Korea Spain Switzerland Taiwan Thailand United Kingdom

References

Explore related publications, articles, or registry entries linked to this study.

Martin M, Bonneterre J, Geyer CE Jr, Ito Y, Ro J, Lang I, Kim SB, Germa C, Vermette J, Wang K, Wang K, Awada A. A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer. Eur J Cancer. 2013 Dec;49(18):3763-72. doi: 10.1016/j.ejca.2013.07.142. Epub 2013 Aug 15.

Reference Type DERIVED
PMID: 23953056 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

3144A2-3003 / B1891003

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Lapatinib in Combination With Vinorelbine
NCT01128543 COMPLETED PHASE2